| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 648 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 |
| Total Income - EUR | 26.171 | 7.759 | 7.640 | 7.500 | 7.354 | 7.214 | 6.428 | 925 | - | 348 |
| Total Expenses - EUR | 35.478 | 23.423 | 21.750 | 15.563 | 9.050 | 8.992 | 7.390 | 3.671 | - | 3.413 |
| Gross Profit/Loss - EUR | -9.307 | -15.664 | -14.110 | -8.063 | -1.696 | -1.778 | -962 | -2.747 | - | -3.065 |
| Net Profit/Loss - EUR | -9.327 | -15.664 | -14.110 | -8.063 | -1.696 | -1.778 | -962 | -2.747 | - | -3.065 |
| Employees | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | - | 0 |
Check the financial reports for the company - Genome Life Research Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 56.082 | 46.142 | 36.873 | 27.864 | 19.153 | 10.774 | 3.392 | 696 | - | 0 |
| Current Assets | 15.593 | 1.244 | 1.574 | 1.856 | 1.817 | 1.764 | 2.039 | 2.046 | - | 2.028 |
| Inventories | 0 | 0 | 0 | 753 | 739 | 725 | 709 | 711 | - | 705 |
| Receivables | 14.298 | 1.180 | 1.565 | 1.109 | 1.087 | 1.048 | 1.339 | 1.343 | - | 1.332 |
| Cash | 1.294 | 64 | 9 | -6 | -9 | -9 | -9 | -9 | - | -9 |
| Shareholders Funds | -48.534 | -63.703 | -76.735 | -83.389 | -83.470 | -83.665 | -82.505 | -84.543 | - | -84.158 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | - | 40 |
| Debts | 68.367 | 111.089 | 82.384 | 88.511 | 87.581 | 86.874 | 85.242 | 85.506 | - | 84.771 |
| Income in Advance | 52.386 | 41.133 | 32.797 | 24.696 | 16.864 | 9.330 | 2.695 | 1.778 | - | 1.415 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7211 - 7211" | |||||||||
| CAEN Financial Year |
7211
|
|||||||||
Comments - Genome Life Research Srl